engleski

Spectrum of radiological imaging findings of specific target therapy for lung cancer at University hospital centre Osijek

Discovery of oncogenic driver mutations and precise targeted therapy directed at these mutations have resulted in progress for treatment approaches in patients with advanced lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are two well-known oncogenic mutations in NSCLC, particularly in adenocarcinomas, and are representative examples of successful clinical application of precision lung cancer therapy, just like the ROS1 mutation, which is less pronounced. Some of specific target therapies had a superior efficacy in the central nervous system (CNS), reducing the risk of CNS progression. The abstract is intended to demonstrate how the key members of multidisciplinary teams care for patients with NSCLC.

ALK ; EGFR ; chest CT ; NSCLC ; RECIST

nije evidentirano